Peregrine Pharmaceuticals (NASDAQ:PPHM)‘s stock had its “buy” rating reissued by investment analysts at Noble Financial in a research note issued to investors on Friday.
Several other research firms have also issued reports on PPHM. ValuEngine lowered shares of Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research raised shares of Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 18th.
Peregrine Pharmaceuticals (NASDAQ PPHM) traded up $0.03 during trading on Friday, reaching $4.22. 93,094 shares of the company traded hands, compared to its average volume of 242,010. The stock has a market cap of $189.44, a price-to-earnings ratio of -5.21 and a beta of 2.74. Peregrine Pharmaceuticals has a one year low of $1.97 and a one year high of $5.78.
COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/01/06/peregrine-pharmaceuticals-pphm-buy-rating-reaffirmed-at-noble-financial.html.
Peregrine Pharmaceuticals Company Profile
Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.
Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.